New sustainable concrete with recycled aggregates and recycled tyre steel fibres towards net zero transition

The Fragment-Based Drug Discovery project, spearheaded by Professors Roper and Scanlon, addresses a critical global health challenge: antibiotic resistance. By targeting bacterial cell wall biosynthesis, a vital process for bacterial survival, this research aims to discover novel antibiotic drug targets to counter drug-resistant bacterial infections. Leveraging a strategic partnership between Monash University and the University of Warwick, this initiative combines expertise in chemistry and microbiology to develop effective, long-lasting solutions for one of today’s most pressing medical challenges. Success in this project could significantly reduce mortality from resistant infections, improving healthcare resilience globally.

This collaboration exemplifies a robust partnership, pooling the strengths of Monash’s Fragment Platform (MFP) with Warwick’s established protocols in bacterial cell wall biology. Professor Roper’s team at Warwick brings extensive experience in glycosyltransferase (GT) enzyme inhibition, while Professor Scanlon’s team at Monash contributes advanced chemoinformatics and drug discovery methods. Together, they tackle the complexity of bacterial cell wall biosynthesis with a multidisciplinary approach that combines insights from microbiology, chemistry, and structural biology. This synergy enables a comprehensive, boundary-crossing framework for antibiotic discovery.

A transdisciplinary approach defines the project, integrating diverse fields and resources from both institutions to innovate beyond conventional research boundaries. The MFP provides Monash with Warwick’s unique plasmid protocols and structural biology tools, enabling in-depth exploration of GT enzyme inhibition. By targeting lipid II polymerisation, an essential process in bacterial cell wall formation, this research aims to halt bacterial growth and cause cell lysis, offering a promising pathway toward clinical application. Validating assays at both universities accelerates this translational research, ensuring it focuses on delivering tangible health outcomes.

This project underscores the potential for lasting societal impact by addressing an immediate global health need with sustainable solutions. Building on previously identified fragment hits, the team will conduct structure-activity relationship (SAR) studies and screen analogues to identify lead compounds. This structured, systematic approach addresses the urgent need for effective antibiotics and builds a foundation for next-generation antibiotic research. Aligning with Monash University’s 2030 vision, the project promises to enhance public health, addressing global challenges through science and innovation.

In summary, the Fragment-Based Drug Discovery project is essential in combating antibiotic resistance. Its transdisciplinary approach, solid international partnership, and focus on real-world impact position it to create meaningful advancements in antibiotic research, helping to protect future generations against one of the greatest threats to global health.

Principle applicants

Professor Martin Scanlon Director ARC Industry Transformation Training Centre for Fragment Based Design (CFBD) Monash Institute of Pharmaceutical Sciences Monash University	Professor David Roper Professor of Biochemistry and Director of Research School of Life Sciences University of Warwick